Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 2Northera

02 4Northera

PharmaCompass

01

Brand Name : Northera

Droxidopa

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Northera

arrow
Pharmtech & Ingredients
Not Confirmed

Droxidopa

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 415

2019 Revenue in Millions : 379

Growth (%) : 10

blank

02

Brand Name : Northera

Droxidopa

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Northera

arrow
Pharmtech & Ingredients
Not Confirmed

Droxidopa

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 101

2020 Revenue in Millions : 408

Growth (%) : -74

blank

03

Brand Name : Northera

Droxidopa

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Northera

arrow
Pharmtech & Ingredients
Not Confirmed

Droxidopa

Main Therapeutic Indication : Neurogenic Orthostatic Hypotension

Currency : USD

2015 Revenue in Millions : 4

2014 Revenue in Millions : 71

Growth (%) : 1675%

blank

04

Brand Name : Northera

Droxidopa

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Northera

arrow
Pharmtech & Ingredients
Not Confirmed

Droxidopa

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 279

2016 Revenue in Millions : 185

Growth (%) : 51

blank

05

Brand Name : Northera

Droxidopa

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Northera

arrow
Pharmtech & Ingredients
Not Confirmed

Droxidopa

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 271

2017 Revenue in Millions : 247

Growth (%) : 10%

blank

06

Brand Name : Northera

Droxidopa

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Northera

arrow
Pharmtech & Ingredients
Not Confirmed

Droxidopa

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 349

2018 Revenue in Millions : 271

Growth (%) : 29

blank